Storm Therapeutics, a company focused on the discovery of small molecule therapies has appointed Professor Thomas Cech as its scientific advisor.
Professor Cech’s career has seen him spend decades researching into RNA biology and he became the scientific founder of Ribozyme Pharmaceuticals. He currently serves on the board of directors of Merck & Co.
Commenting on the new appointments, Keith Blundy, chief executive officer of Storm Therapeutics, said: “We are very pleased to have attracted such an internationally renowned researcher as Professor Cech to Storm.
“As a leader in the field of RNA biology, Tom’s in-depth knowledge, insight and experience will be invaluable as we look to continue building a drug discovery platform and mature into a world leading therapeutics company targeting RNA epigenetic modulation.”
His new role will see him join recent hires Professor Mark Dawson and Dr Paul Leeson to boost Storm’s pipeline.